ArticleBMC medical imaging2025
Deep learning-based MRI model for predicting P53-mutated hepatocellular carcinoma.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A novel deep learning and radiomics approach based on DCE-MRI for predicting the P53 mutation status in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2026Article
- An MRI-Based Intratumoral and Peritumoral 2.5D Deep Learning Model for Predicting P53-Mutated Hepatocellular Carcinoma: A Two-Center Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe P53-mutated Hepatocellular Carcinoma (HCC) is an aggressive variant associated with vascular endothelial growth factor (VEGF) overexpression and increased microvascular density. This study aimed to develop an MRI-based deep learning model for predicting P53-mutated HCC.
methodsA total of 312 HCC patients who underwent gadolinium-enhanced MRI and were pathologically confirmed between January 2018 and December 2023 were retrospectively enrolled. Participants were randomly divided into training and test dataset at an 8:2 ratio. We developed an EfficientNetV2-based deep learning model, constructing arterial phase (AP) model, portal venous phase (VP), T2-weighted imaging (T2WI), hepatobiliary phase (HBP) single-sequence model, and combined models to predict P53 mutation status. Model performance was evaluated using the area under the curve (AUC), accuracy, sensitivity, specificity, precision, and F1 score as metrics. Differences in AUC values were compared using Delong's test.
resultsA total of 312 pathologically confirmed HCC patients (age: 56 ± 9 years; male = 240) were included, with a training dataset (n = 249) and test dataset (n = 63).Among single-sequence models, the HBP model demonstrated superior diagnostic performance (AUC = 0.715) compared to T2WI, AP, and VP models. The multiphase combined model (T2WI + AP + VP) significantly outperformed single-sequence models, achieving AUCs of 0.982 (95% CI: 0.959-1.000) in the training dataset and 0.914 (95% CI: 0.819-1.000) in the test dataset. However, incorporating the HBP sequence into the combined model (T2WI + AP + VP + HBP) did not further improve diagnostic performance (P > 0.05). ADVANCES IN KNOWLEDGE: The combined model incorporating AP, VP, T2WI, and HBP sequences demonstrated numerically highest performance in predicting P53-mutated HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.